Pharmaceutical composition for oral use with improved absorption
The present invention relates to an agent for inhibiting decomposition of a biologically active peptide by a digestive enzyme, which is aminoalkyl methacrylate copolymer E as an effective ingredient, and an agent for reducing viscosity of the gastrointestinal mucosa and mucous layers distributed over this mucosa. The present invention relates to a method for inhibiting decomposition of a biologically active peptide by a digestive enzyme, or a method for reducing viscosity of the gastrointestinal mucosa and/or mucous layers distributed over the mucosa, by administration of aminoalkyl methacrylate copolymer E. Furthermore, the present invention relates to a pharmaceutical composition for oral use with improved absorption, which comprises a biologically active peptide and aminoalkyl methacrylate copolymer E. Excellent oral absorption of a biologically active peptide that were considered difficult to absorb by oral administration in the past, can be realized based on the ability to inhibit decomposition of a biologically active peptide, the ability to reduce viscosity of the gastrointestinal mucosa and/or mucous layers distributed over this mucosa, and the ability to improve permeability of a biologically active peptide in the gastrointestinal mucosa and/or mucous layers of the pharmaceutical composition of the present invention.
1. A method for inhibiting decomposition of a biologically active peptide, said method comprising orally administering an aminoalkyl methacrylate copolymer E, which is a copolymer of methyl methacrylate, butyl methacrylate, and dimethylaminoethyl methacrylate, to prevent decomposition of said biologically active peptide by a digestive enzyme, wherein said aminoalkyl methacrylate copolymer E is used in the presence of an acidic substance, said acidic substance being an inorganic acid or an organic acid; wherein the amount of the acidic substance added is 0.005-50 parts by weight per 1 part by weight of aminoalkyl methacrylate copolymer E; and
wherein the active peptide is formed into a member selected from the group consisting of a tablet, a pill, a liquid, a suspension, an emulsion, and a capsule.
2. The method according to claim 1 , wherein the digestive enzyme is trypsin or elastase.
3. The method according to claim 1 , wherein the amount of aminoalkyl methacrylate copolymer E is 0.1 part by weight or more per one part by weight of said biologically active peptide.
4. The method according to claim 1 , wherein the amount of the acidic substance added is the amount to neutralize 15% to 50% of the basic groups of aminoalkyl methacrylate copolymer E.
5. The method according to claim 1 , wherein said biologically active peptide and aminoalkyl methacrylate copolymer E are comprised in a pharmaceutical composition.
6. The method according to claim 5 , wherein the pharmaceutical composition comprises said biologically active peptide, aminoalkyl methacrylate copolymer E, and an acidic substance, wherein said three components are brought together and at least said polymer and said acidic substance are uniformly mixed.
7. The method according to claim 6 , wherein said biologically active peptide, aminoalkyl methacrylate copolymer E, and said acidic substance are uniformly mixed.
8. The method according to claim 6 or 7 , wherein the amount of aminoalkyl methacrylate copolymer E added is 0.1 part by weight or more per one part by weight of said biologically active peptide.
9. The method according to claim 6 or 7 , wherein the amount of acidic substance added is the amount to neutralize 10% to 40% of the basic groups of aminoalkyl methacrylate copolymer E.
10. The method according to claim 6 or 7 , wherein aminoalkyl methacrylate copolymer E and the acidic substance are granulated.
11. The method according to claim 6 or 7 , wherein the pharmaceutical composition is obtained by dissolving and/or dissolving aminoalkyl methacrylate copolymer E and acidic substance in a pharmaceutically acceptable solvent and spray drying to produce a spray-dried substance, or freeze-drying to produce a freeze-dried substance after dissolution.
12. The method according to claim 11 , wherein aminoalkyl methacrylate copolymer E and the acidic substance are dissolved and/or suspended in a pharmaceutically acceptable solvent.
13. The method according to claim 6 or 7 , wherein the form of the pharmaceutical preparation is one or two or more selected from the group consisting of a tablet, a capsule, and a liquid.
14. The method according to claim 6 or 7 , wherein the biologically active peptide is one of that is decomposed by a digestive enzyme and/or one of that is difficult to absorb.
15. The method according to claim 14 , wherein the biologically active peptide is calcitonin, insulin, or vasopressin.